As we move into summer 2025, it’s a great time for psych NPs to stay updated on the newest psychotropic medication updates. Just as the season shifts, so does the landscape of psychiatric pharmacology — with exciting new drug approvals and treatments emerging.
Though the warm, rainy weather here in Columbus, Ohio may still feel more like late spring, the changes happening in science and medicine are definitely in full swing. Our field is always evolving, especially when it comes to new medications that can improve patient care.
In 2024, the FDA approved 50 new drugs, including one notable psychotropic medication. On September 26, 2024, the FDA approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia.
Fast Facts About Cobenfy:
- FDA-approved on September 26, 2024 for schizophrenia
- First new psychosis medication that does not act on dopamine receptors
- Targets cholinergic receptors instead
- Shown to improve negative symptoms of schizophrenia, not just positive symptoms
- Approval based on 5-week double-blind, placebo-controlled trials
- Common side effects include nausea, constipation, and tachycardia
- Insurance coverage availability is still uncertain
Before Cobenfy, here are some recent FDA psychotropic approvals:
- Exxua (gepirone): Approved September 2023 for Major Depressive Disorder (MDD) in adults
- Zurzuvae (zuranolone): Approved August 2023, first oral treatment for postpartum depression in adults
- Auvelity (dextromethorphan and bupropion): Approved 2022 for MDD in adults
Why Staying Current on Psychotropic Medication Updates Matters for Psych NPs
Personally, I tend to be cautious prescribing newly approved medications. It’s wise to observe longer-term outcomes and side effects over several years before incorporating new drugs into routine practice.
Anyone remember the injectable form of Zyprexa? It was pulled back from widespread use after concerns about post-injection delirium and fatalities. This highlights why staying updated is crucial, but immediate adoption isn’t always best.
If you want to dive deeper, the FDA’s novel drug approvals list is a great resource to track upcoming medication updates.
As the field continues to evolve, keeping up with psychotropic medication updates will empower psych NPs to make informed decisions and offer innovative treatments to their patients.
Here’s to staying informed and keeping our patients safe this summer and beyond!